CRSP.O

CRSP.O has a highly liquid capital structure, with a current ratio of 13.32, indicating strong short-term liquidity. The company is entirely equity-funded, with no long-term debt, and a debt-to-equity ratio of 0.0. However, the company is experiencing negative cash flows, with operating cash flow of -$345.01 million and free cash flow of -$588.03 million. This suggests that the company is not generating sufficient cash from operations to sustain its activities and is likely relying on equity financing or asset sales to fund operations. Profitability metrics are deeply negative, with a return on equity of -30.26% and a return on assets of -25.67%. These figures are significantly below the industry median for biotechnology and medical research firms, which typically exhibit positive returns during growth phases. The company reported a net loss of $581.60 million and an operating loss of $664.57 million, indicating that it is not yet achieving operational profitability. The company's revenue is concentrated in a single business line, as disclosed in its financial segments, with no geographic diversification provided in the available data. This lack of diversification increases exposure to sector-specific risks, such as regulatory changes or shifts in healthcare reimbursement models. No specific geographic breakdown is available in the current dataset, but the absence of international revenue reporting suggests a U.S.-centric business model. Growth trajectory is currently negative, with the company reporting a revenue of $3.51 billion but experiencing a net loss of $581.60 million. Analysts have provided a wide range of price targets, from $33.00 to $291.00, with a mean of $81.25 and a median of $78.00. The mean recommendation score of 2.21 suggests a generally positive outlook, but the wide dispersion in price targets indicates uncertainty about the company's future performance. No specific revenue growth rates or outlooks for the current or next fiscal year are provided in the available data. Risk factors include the company's negative cash flows and net losses, which could lead to increased reliance on equity financing. The risk assessment indicates low dilution risk, but the company's negative free cash flow and operating cash flow suggest potential liquidity challenges if equity financing is not sustained. No immediate filing-based liquidity or dilution flags were detected, but the company's financial position remains precarious without a path to positive cash flow. Recent events include the publication of the latest financial data, which shows continued losses and negative cash flows. No specific recent filings or transcripts are available in the current dataset, but the company's financial performance suggests ongoing operational challenges that may require strategic adjustments or additional capital.